Tarsus Pharmaceuticals Inc. (NASDAQ:TARS) shares traded -5.53% lower at $17.26 on Wall Street last session.
In accordance with the data, 9 analysts cover Tarsus Pharmaceuticals Inc. (NASDAQ:TARS). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $70.00 and a low of $40.00, we find $52.00. Given the previous closing price of $18.27, this indicates a potential upside of 184.62 percent. TARS stock price is now -6.44% away from the 50-day moving average and 7.51% away from the 200-day moving average. The market capitalization of the company currently stands at $464.29M.
It has been rated a hold by 0 analysts and a buy by 8. Brokers who have rated the stock have averaged $53.13 as their price target over the next twelve months.
With the price target of $44, William Blair recently initiated with Outperform rating for Tarsus Pharmaceuticals Inc. (NASDAQ: TARS).
In other news, Azamian Bobak R., President/CEO and Board Chair sold 103,900 shares of the company’s stock on Jul 19. The stock was sold for $2,078,984 at an average price of $20.01. Upon completion of the transaction, the President/CEO and Board Chair now directly owns 910,106 shares in the company, valued at $15.71 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jul 19, Chief Commercial Officer Mottiwala Aziz sold 2,400 shares of the business’s stock. A total of $48,120 was realized by selling the stock at an average price of $20.05. This leaves the insider owning 45,806 shares of the company worth $0.79 million. Insiders disposed of 1,117,466 shares of company stock worth roughly $19.29 million over the past 1 year. A total of 5.50% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in TARS stock. A new stake in Tarsus Pharmaceuticals Inc. shares was purchased by GRANT/GROSSMENDELSOHN, LLC during the first quarter worth $926,000. SG AMERICAS SECURITIES, LLC invested $718,000 in shares of TARS during the first quarter. In the first quarter, JANNEY MONTGOMERY SCOTT LLC acquired a new stake in Tarsus Pharmaceuticals Inc. valued at approximately $375,000. D. E. SHAW & CO., INC. acquired a new stake in TARS for approximately $303,000. RAYMOND JAMES FINANCIAL SERVICES ADVISORS, INC. purchased a new stake in TARS valued at around $291,000 in the second quarter. In total, there are 129 active investors with 77.10% ownership of the company’s stock.
Tarsus Pharmaceuticals Inc. (NASDAQ: TARS) opened at $17.47 on Wednesday. During the past 12 months, Tarsus Pharmaceuticals Inc. has had a low of $11.33 and a high of $25.25. As of last week, the company has a debt-to-equity ratio of 0.14, a current ratio of 15.70, and a quick ratio of 15.70. The fifty day moving average price for TARS is $18.47 and a two-hundred day moving average price translates $16.05 for the stock.
The latest earnings results from Tarsus Pharmaceuticals Inc. (NASDAQ: TARS) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$0.88, beating analysts’ expectations of -$0.94 by 0.06. This compares to -$0.98 EPS in the same period last year. The company reported revenue of $2.5 million for the quarter, compared to $0.54 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 363.82 percent. For the current quarter, analysts expect TARS to generate $1.47M in revenue.
Tarsus Pharmaceuticals Inc.(TARS) Company Profile
Tarsus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
